AstraZeneca's top-selling cancer drug sees early unblinding in key trial [Reuters]
AstraZeneca PLC - American Depositary Shares (AZN)
Last astrazeneca plc - american depositary shares earnings: 2/5 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
astrazeneca.com/investor-relations.html
Company Research
Source: Reuters
AstraZeneca's top-selling cancer drug sees early unblinding in key trial (Reuters) - AstraZeneca Plc said the third phase trial of its top-selling cancer drug Tagrisso, aimed at showing the drug’s benefit in lung cancer treatment, will be unblinded early after a recommendation from an independent data monitoring committee. José Baselga, executive vice president, Oncology R&D, said the company was thrilled by the recommendation to unblind the trial much earlier than expected “and are incredibly excited with these unprecedented results in patients with early-stage EGFR-mutated non-small cell lung cancer.” The British drug maker said the data will be presented at a forthcoming medical meeting. Last year, AstraZeneca said a late-stage study showed Tagrisso had significantly helped patients with a type of lung cancer live longer. The company has moved deeper into cancer therapy through wide-ranging deals, including for immunotherapy and targeted therapy. Last year, it agreed a multi-billio
Show less
Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZN alerts
High impacting AstraZeneca PLC - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AZN
News
- China's Licensing Trends Shaping Global Drug Development Analysis Report 2025: Parent Companies Benefitted from Upfront Payments for R&D, Gaining Equity in Novel Chinese Therapeutics [Yahoo! Finance]Yahoo! Finance
- Has AstraZeneca's Strong 30% Rally Left Further Upside in 2025? [Yahoo! Finance]Yahoo! Finance
- Massive U.S. drug spending gives Trump trade leverage [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASHBusiness Wire
- Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term [Yahoo! Finance]Yahoo! Finance
AZN
Sec Filings
- 12/4/25 - Form 6-K
- 12/1/25 - Form 6-K
- 12/1/25 - Form 6-K
- AZN's page on the SEC website